Low-Dose Radiation Therapy for Diffuse Large B-Cell Lymphoma

This trial explores a new treatment method for diffuse large B-cell lymphoma (DLBCL), a type of blood cancer. Researchers aim to determine if low-dose radiation therapy (LDRT) combined with standard chemoimmunotherapy can effectively target remaining cancer cells. The trial will test this approach on patients whose cancer appears in blood tests after initial treatment, while those without detectable cancer will continue regular treatment. This trial may suit adults newly diagnosed with DLBCL who plan to undergo chemoimmunotherapy. As a Phase 2 trial, it measures the treatment's effectiveness in an initial, smaller group, offering participants a chance to contribute to important research.

The trial protocol does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial team or your doctor.

Research has shown that low-dose radiation therapy (LDRT) is generally safe for patients with certain types of lymphoma, such as diffuse large B-cell lymphoma (DLBCL). One study found that using LDRT at doses like 2 × 2 Gy (a measure of radiation) effectively treated slower-growing lymphomas without major side effects. Another study found that LDRT at a dose of 8 Gy, administered in two parts, performed similarly to other radiation schedules but was less effective in preventing disease progression over time. Overall, studies have demonstrated that LDRT is a safe option, making it a promising choice for those with DLBCL.¹²³⁴⁵

Most treatments for diffuse large B-cell lymphoma (DLBCL) involve chemotherapy and immunotherapy, typically working to kill cancer cells throughout the body. However, low-dose radiation therapy (LDRT) offers a unique approach by targeting specific sites with cancer activity, as identified by PET scans. This precision allows LDRT to focus on areas where residual disease is still present after initial treatment cycles, potentially improving outcomes without affecting the entire body. Researchers are excited because this targeted method may enhance the effectiveness of standard treatments while minimizing side effects.

Studies have shown that low-dose radiation therapy (LDRT) can effectively treat diffuse large B-cell lymphoma (DLBCL). Research indicates that a lower radiation dose of about 20 Gy can still be effective for this type of lymphoma. In some cases, patients experienced high rates of cancer not returning in the treated area, with rates of 98.7% and 97.4% at 3 and 5 years after treatment, respectively. Additionally, the rates of patients living without cancer worsening were 91.7% and 87.2% at these same time points. In this trial, participants with detectable circulating tumor DNA minimal residual disease (ctDNA MRD) after cycle 2 of frontline chemoimmunotherapy and residual PET-avid disease may receive LDRT in addition to standard systemic therapy. This suggests that LDRT could be a promising option for managing DLBCL when guided by specific testing methods.²⁶⁷⁸⁹